Inventiva faces resistance but has solid fundamentalsInventiva SAEURONEXT_DLY:IVAHibou68On an uptrend near the 210-day MA (30 weeks) (Wall around €5). Key takeaways: - Clinical advances on lanifibranor - Financing and partnerships (including rumors from US pharmaceutical giants) - Cash flow increasing until mid-2026. Analysts' speculative price target around €8. Everything will depend on the feedback from lanifibranor's advances. The Chinese paid $10 million as part of a partnership. I have a PRU of €2.93. I'm sticking with this company for the long term.